Guardant Health (NASDAQ:GH) Stock: Insider Alex Azar II Sells 69 Shares

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Alex Azar II sold 69 shares of the company’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $149.56, for a total value of $10,319.64. Following the sale, the director owned 962 shares of the company’s stock, valued at approximately $143,876.72. This trade represents a 6.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Performance

GH stock opened at $145.14 on Thursday. Guardant Health, Inc. has a fifty-two week low of $74.55 and a fifty-two week high of $191.05. The business’s 50-day moving average is $167.58 and its two-hundred day moving average is $133.48. The company has a market cap of $19.64 billion, a price-to-earnings ratio of -39.44 and a beta of 1.67.

Guardant Health (NASDAQ:GH – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.74) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GH. Guggenheim increased their price objective on shares of Guardant Health from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Roth Capital started coverage on shares of Guardant Health in a research report on Thursday, October 22nd. They set a “buy” rating and a $200.00 target price for the company. Mizuho upped their target price on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. UBS Group increased their price target on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Morgan Stanley lifted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.88.

Read Our Latest Stock Analysis on Guardant Health

Institutional Trading of Guardant Health

Several hedge funds have recently bought and sold shares of the stock. Financial Network Wealth Advisors LLC increased its holdings in Guardant Health by 17.2% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock worth $75,000 after acquiring an additional 62 shares in the last quarter. Yousif Capital Management LLC raised its stake in Guardant Health by 6.2% during the 3rd quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock worth $283,000 after acquiring an additional 93 shares during the period. Allworth Financial LP lifted its holdings in Guardant Health by 12.4% during the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after purchasing an additional 118 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after purchasing an additional 122 shares in the last quarter. Finally, Slow Capital Inc. lifted its holdings in Guardant Health by 0.3% during the third quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock valued at $9,397,000 after purchasing an additional 136 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

Featured Articles

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.